PamBio Overview
- Founded
- 2014
- Status
- Out of Business
- Latest Deal Type
- Out of Business
PamBio General Information
Description
Developer of drug therapy intended to treat acute bleeding conditions. The company's therapy helps in stabilizing blood clots, increasing anti-bleeding treatment time-window beyond 3 hours, minimizing blood toxicity in the brain and has reduced side effects, enabling physicians to treat their patients in an enhanced way.
Contact Information
Website
Ownership Status
Out of Business
Financing Status
Formerly Accelerator/Incubator backed
Primary Industry
Drug Discovery
Other Industries
Other Pharmaceuticals and Biotechnology
Biotechnology
Primary Office
- NGT3 VC Technological Incubator
- P.O. Box 1252
- Nazareth Illit 17111
- Israel
+972 00-000-0000
PamBio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Out of Business | 0000 | Completed | Out of Business | |||
| 2. Angel (individual) | 18-Jul-2016 | 000 | 0000 | Completed | Startup | |
| 1. Accelerator/Incubator | $3M | $3M | Completed | Startup |
PamBio Executive Team (4)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Amos Ofer Ph.D | Chief Executive Officer | ||
| Abd Higazi MD | Co-Founder & Chief Scientific Officer | ||
| Nuha Higazi Ph.D | Co-Founder & Chief Technology Officer |
PamBio Board Members (3)
| Name | Representing | Role | Since |
|---|---|---|---|
| Noa Shelach Ph.D | PamBio | Board Member | 000 0000 |